Jpmorgan Chase & CO Concert Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$4.34 - $5.84 $811,211 - $1.09 Million	186,915 Added 213.94%	274,282 $1.6 Million
Q3 2022 Nov 14, 2022	BUY	$4.27 - $7.2 $175,146 - $295,329	41,018 Added 88.5%	87,367 $585,000
Q2 2022 Aug 11, 2022	BUY	$2.8 - $6.36 $129,659 - $294,512	46,307 Added 110254.76%	46,349 $195,000
Q4 2021 Feb 10, 2022	SELL	$2.69 - $4.22 $6,084 - $9,545	-2,262 Reduced 98.18%	42 $0
Q3 2021 Nov 12, 2021	BUY	$3.17 - $4.15 $7,303 - $9,561	2,304 New	2,304 $8,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.